Literature DB >> 27810401

Additional mailing phase for FIT after a medical offer phase: The best way to improve compliance with colorectal cancer screening in France.

Christine Piette1, Gérard Durand1, Jean-François Bretagne2, Jean Faivre3.   

Abstract

BACKGROUND: Compliance with colorectal cancer screening is critical to its effectiveness. The organisation of the mass screening programme in France has recently been modified with no evaluation of the consequences. AIMS: To evaluate the impact of the way the screening test is delivered on compliance. PATIENTS AND METHODS: During the first six months of the screening campaign (Ille-Vilaine, Brittany), general practitioners were asked to propose a faecal immunochemical test (FIT), OC-Sensor, to individuals at average risk for colorectal cancer (n=152,097). A subset of non-participants in the medical phase (n=13,071) was randomly chosen to receive a reminder that included the screening test or a simple postal reminder without the screening test.
RESULTS: Compliance was 31% if the screening test was proposed during a medical consultation. In non-participants during the medical phase, it was 45% in those receiving both a reminder and the screening test and 28% amongst those receiving a simple reminder. An estimated overall participation rate of 54% can be expected if non-participants in the medical phase are sent a reminder together with the screening test.
CONCLUSION: In France, a compliance rate above the minimum uptake rate of 45% recommended by European Union experts can be achieved if the FIT is mailed to non-participants after the medical free-offer phase.
Copyright © 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Colorectal cancer; Compliance; Immunochemical test; Screening

Mesh:

Year:  2016        PMID: 27810401     DOI: 10.1016/j.dld.2016.09.015

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  6 in total

1.  Effect of Physician Notification Regarding Nonadherence to Colorectal Cancer Screening on Patient Participation in Fecal Immunochemical Test Cancer Screening: A Randomized Clinical Trial.

Authors:  Cédric Rat; Corinne Pogu; Delphine Le Donné; Chloé Latour; Gaelle Bianco; France Nanin; Anne Cowppli-Bony; Aurélie Gaultier; Jean-Michel Nguyen
Journal:  JAMA       Date:  2017-09-05       Impact factor: 56.272

2.  Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner.

Authors:  Elisabeth F P Peterse; Caroline B Osoro; Marc Bardou; Iris Lansdorp-Vogelaar
Journal:  Aliment Pharmacol Ther       Date:  2021-03-08       Impact factor: 8.171

3.  Results of the national organised colorectal cancer screening program with FIT in Paris.

Authors:  Anna Pellat; Jacques Deyra; Romain Coriat; Stanislas Chaussade
Journal:  Sci Rep       Date:  2018-03-07       Impact factor: 4.379

4.  Does mammogram attendance influence participation in cervical and colorectal cancer screening? A prospective study among 1856 French women.

Authors:  Aurélie Bertaut; Julien Coudert; Leila Bengrine; Vincent Dancourt; Christine Binquet; Serge Douvier
Journal:  PLoS One       Date:  2018-06-21       Impact factor: 3.240

5.  Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe.

Authors:  Esther Toes-Zoutendijk; Isabel Portillo; Sarah Hoeck; Isabel de Brabander; Philippe Perrin; Catherine Dubois; Monique van Leerdam; Iris Lansdorp-Vogelaar; Marc Bardou
Journal:  J Med Screen       Date:  2019-10-23       Impact factor: 2.136

6.  Colorectal cancer screening by fecal immunochemical test or colonoscopy in France: how many people are actually covered? Focus on the Provence-Alpes-Côte d'Azur region.

Authors:  Jean-François Seitz; David Lapalus; Sylvie Arlotto; Stéphanie Gentile; Florence Ettori; Yves Rinaldi; Philippe Grandval; Patrick Delasalle
Journal:  Eur J Gastroenterol Hepatol       Date:  2022-04-01       Impact factor: 2.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.